Scientific information remains useful only when its source, methods, population and limitations stay attached to the reported result.

Begin with the question the study actually asked

A randomized trial, a mechanistic laboratory experiment and an observational study answer different questions. Before interpreting any result, identify the design, population, comparator, duration and prespecified endpoint.

Transparent reporting matters because a reader cannot judge reliability when allocation, participant flow, outcomes or missing data are unclear. The CONSORT framework was developed to improve reporting of randomized trials and support critical appraisal.

Evidence should become more specific as a claim becomes more consequential.

Keep the endpoint attached to the population

Look for the number of participants analysed, the comparison group, absolute and relative changes, confidence intervals, adverse-event reporting and whether the reported endpoint was defined before analysis.

Published Tesamorelin and Retatrutide trials illustrate why context cannot be removed: each investigated a specified intervention, dose, population and follow-up period under a controlled protocol. Those findings do not establish the identity, purity, safety or performance of a separate research material.

The EternaGen reporting standard
  • Link to the original source.
  • Name the study design and population.
  • Report the observed endpoint factually.
  • Disclose important limitations.
  • Never convert trial reporting into a product recommendation.

A published result is not a universal conclusion

Short follow-up, selective eligibility criteria, surrogate endpoints, attrition and sponsor involvement can affect interpretation. A statistically significant result does not automatically establish clinical importance or applicability outside the study population.

EternaGen reports study context for education only and does not translate published findings into product recommendations or directions for human use.

Primary references

These sources were checked against the linked publisher, regulator or literature-index record on 20 July 2026.

  1. Moher et al. CONSORT 2010 Explanation and Elaboration. J Clin Epidemiol. 2010. PMID 20346624.
  2. Falutz et al. Effects of tesamorelin in HIV-associated abdominal fat accumulation. J Acquir Immune Defic Syndr. 2010. PMID 20101189.
  3. Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315.
Educational content only. This article does not constitute medical advice, a therapeutic claim or a recommendation for human or veterinary use.